all: what % of LLY 's sales cme from Evista? Looks like LLY does not want to go
down... sales forcast of evista reduced by 50%? I have not followed this stock for a
while, any opinion would be appriciated. Considering going long?
thanks in advance.
sonki btw: long pfe, wla, mrk also.
RESEARCH ALERT - Eli Lilly downgraded
NEW YORK, March 25 (Reuters) - Salomon Smith Barney said on Wednesday it lowered its rating on shares of Eli Lilly and Co to outperform from buy.
-- Analyst Christina Heuer said in a research note the launch of Lilly's raloxifene, or Evista, its drug to prevent osteoporosis, has been disappointing.
-- She lowered 1998 Evista sales estimate to $180 million from $375 million and 2002 Evista sales estimate to the $2 billion level from the $3 billion level.
-- ''Unfortunately Lilly's new drug launches are sparse until 2001, when a burst of six is anticipated,'' she said. ''So there are no other major new drug introductions to
make up for the shortfall in Evista.''
-- Heuer said she had thought a large pool of post-menopausal women who had discontinued estrogen replacement therapy due to breast cancer risk would flock to
Evista to prevent osteoporosis, but this has not occured.
-- Shortfall in Evista increases Lilly's exposure to Prozac generic cannibalization risk, she said. |
